Boston Scientific's ($BSX) launch of its below-the-knee, everolimus-eluting stent system to treat critical limb ischemia, known as Promus Element Plus in Europe, will open up a major potential market for the company--there are around 500 to 1,000 new cases of critical limb ischemia per million people every year in Europe. The disease, which obstructs the arteries and cuts blood flow to the feet and legs, can lead to pain, non-healing wounds, gangrene and even amputation. Stents reopen the blood vessels and the addition of slow-release everolimus helps prevent them from blocking again. Press release